Update on the ARCHES Trial: New Indication for Enzalutamide in mHSPC

Enzalutamide + ADT in Men with De Novo mHSPC: The ARCHES TrialПодробнее

ARCHES trial: enzalutamide plus ADT for mHSPCПодробнее

Update on ARCHES trial: implications for prostate cancer treatmentПодробнее

Update on overall survival in ARCHES trialПодробнее

ENZAMET trialПодробнее

ARCHES trialПодробнее

ARCHES trial: androgen deprivation therapy with enzalutamide or placebo in mHSPCПодробнее

ARCHES: OS by high or low disease volume and progression to mHSPC or de novo mHSPCПодробнее

ARCHES trial overview: ADT plus enzalutamide for metastatic hormone-sensitive prostate cancerПодробнее

ENZAMET & ARCHES Trials Provides Evidence of Enzalutamide as Life Prolonging Therapy in mHSPCПодробнее

Andrew Armstrong, MD, shares updates on the ARCHES study investigating enzalutamide in mPC patientsПодробнее

ARCHES: OS in mHSPC who recieved prior ADT and reached low PSA further treated with enzalutamideПодробнее

ARCHES post-hoc analyses: efficacy of ENZA + ADT in mHSPC by pattern of metastatic spreadПодробнее

Updated overall survival outcomes in ENZAMET (ANZUP 1304)Подробнее

Final OS analysis from ARCHESПодробнее

Andrew Armstrong, MD, presents an overview of the ARCHES trial in mHSPCПодробнее

ARCHES: enzalutamide plus ADT in mHSPC subgroupsПодробнее

Prostate cancer updates: TITAN and ENZAMETПодробнее

Clinical updates for metastatic hormone sensitive prostate cancer at ASCO 2019Подробнее